ViferaXS sammelt in einer Finanzierungsrunde 12 Millionen Euro ein, um die Phase-II-Studie zur chronischen lymphatischen Leukämie voranzutreiben und seine Onkologie-Pipeline auszubauen
ViferaXS, ein Biotechnologieunternehmen im klinischen Stadium, das peptidbasierte Krebsimmuntherapien für hämatologische Malignome und solide Tumoren entwickelt, gab heute den Abschluss einer Serie-A-Finanzierungsrunde in Höhe von bis zu 12 Millionen Euro bekannt, einschließlich Fördermitteln. Die Runde wurde von SPRIND, der Bundesagentur für bahnbrechende Innovationen, und Huma angeführt, unter Beteiligung privater Investoren.
The proceeds will fund ViferaXS’ lead programme, a Phase II clinical trial of CLLTAXS01 in chronic lymphocytic leukemia (CLL), and support ViferaXS’ broader pipeline. In parallel, the financing supports ongoing Phase I programmes in acute myeloid leukemia (AML) and fibrolamellar carcinoma (FLC). Beyond these programs, the round enables ViferaXS to grow its team and advance preclinical work in further indications.
“We are encouraged by the early clinical data of CLLTAXS01, and this financing lets us move that signal into a randomized Phase II study in CLL. We also expect to share Phase I data from our AML and FLC programs soon, so the field can see how a peptide-based cancer immunotherapy approach can potentially transform cancer care for patients,” said Sezai Taskin, Chief Executive Officer of ViferaXS.
“SPRIND believes in challenging the status quo by backing change makers. ViferaXS’ peptide-based cancer immunotherapy approach, and its move into Phase II in CLL, is the kind of clinically grounded, high-ambition work we seek to accelerate. Our goal is to empower novel, breakthrough approaches, which we believe will have a long lasting and breakthrough positive effect on society” said Patrick Rose, PhD, Innovation Manager at SPRIND.
Dan Vahdat, Founder and CEO of Huma, said: “We are building the operating system for clinical trials, bringing data, intelligence and execution into one platform. We are proud to back ViferaXS through both our investment and our technology, helping accelerate its mission to bring new cancer therapies to patients.”
